Jounce Therapeutics Inc (JNCE)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
CEO:
Richard Murray
Employees:
140
780 MEMORIAL DRIVE, CAMBRIDGE, MA 02139
857-259-3840

Jounce Therapeutics, Inc. develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial. It is also developing JTX-8064, an antibody that binds to leukocyte immunoglobulin like receptor B2.

Data derived from most recent annual or quarterly report
Market Cap 251.654 Million Shares Outstanding51.674 Million Avg 30-day Volume 260.471 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-0.59
Price to Revenue0.0 Debt to Equity0.0 EBITDA-254.901 Million
Price to Book Value0.9927 Operating Margin0.0 Enterprise Value-5.671 Million
Current Ratio6.784 EPS Growth-7.433 Quick Ratio6.405
1 Yr BETA 1.3046 52-week High/Low 9.81 / 2.76 Profit Margin0.0
Operating Cash Flow Growth-97.696 Altman Z-Score-2.9672 Free Cash Flow to Firm -55.281 Million
Earnings Report2022-11-03
View SEC Filings from JNCE instead.

View recent insider trading info

Funds Holding JNCE (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding JNCE

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Events (8k)

  • 8-K: filed on 2022-08-04:
    Item 2.02: Results of Operations and Financial Condition
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-06-27:
    Item 5.07: Submission of Matters to a Vote of Security Holders
  • 8-K: filed on 2022-05-05:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-03-07:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-03-02:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-01-10:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 2.02: Results of Operations and Financial Condition
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-11-04:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-11-04:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-09-15:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K: filed on 2021-08-05:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    COLE HUGH M CHIEF OPERATING OFFICER

    • Officer
    166,716 2022-08-01 4

    KARSEN PERRY A

    • Director
    20,000 2022-06-24 1

    DUNCAN BARBARA GAYLE

    • Director
    20,000 2022-06-24 1

    HIGGONS JOHN DUNCAN

    • Director
    20,000 2022-06-24 1

    KAMEN ROBERT

    • Director
    20,000 2022-06-24 1

    DIAZ LUIS

    • Director
    20,000 2022-06-24 1

    IANNONE ROBERT

    • Director
    20,000 2022-06-24 1

    RAYTHATHA JIGAR

    • Director
    20,000 2022-06-24 3

    SALTER-CID LUISA

    • Director
    20,000 2022-06-24 1

    MURRAY RICHARD /CA/ CEO AND PRESIDENT

    • Officer
    • Director
    448,077 2022-02-01 2

    DRAPKIN KIMBERLEE C CFO AND TREASURER

    • Officer
    135,114 2022-02-01 2

    TREHU ELIZABETH CHIEF MEDICAL OFFICER

    • Officer
    167,702 2022-02-01 2

    THIRD ROCK VENTURES III, L.P.

    THIRD ROCK VENTURES GP III, L.P.

    TRV GP III, LLC

    STARR KEVIN P

    TEPPER ROBERT I

    LEVIN MARK J

    • 10% Owner
    4,698,661 2021-11-12 2

    PFEFFER CARY

    • Director
    50,468 2021-11-12 2

    THIRD ROCK VENTURES II, L.P.

    THIRD ROCK VENTURES GP II, L.P.

    TRV GP II, LLC

    STARR KEVIN P

    TEPPER ROBERT I

    LEVIN MARK J

    • 10% Owner
    3,332,638 2021-09-15 2

    GILEAD SCIENCES INC

    • 10% Owner
    5,539,727 2020-10-16 0

    TEPPER ROBERT I

    • Director
    • 10% Owner
    0 2020-06-26 0

    CELGENE SWITZERLAND LLC

    CELGENE CORP /DE/

    • 10% Owner
    3,456,463 2017-02-01 0

    THIRD ROCK VENTURES II, L.P.

    THIRD ROCK VENTURES GP II, L.P.

    TRV GP II, LLC

    THIRD ROCK VENTURES III, L.P.

    THIRD ROCK VENTURES GP III, L.P.

    TRV GP III, LLC

    LEVIN MARK J

    STARR KEVIN P

    • 10% Owner
    3,048,780 2017-02-01 0

    HADLEY HARBOR MASTER INVESTORS (CAYMAN) L.P.

    • 10% Owner
    No longer subject to file 2017-02-01 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed
    Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

    COLE HUGH M - Officer CHIEF OPERATING OFFICER

    2022-08-03 20:29:55 -0400 2022-08-01 A 20,000 a 126,716 direct 14.9171 28.453 35.9116 5 0.0 1

    COLE HUGH M - Officer CHIEF OPERATING OFFICER

    2022-08-03 20:29:55 -0400 2022-08-01 A 40,000 a 40,000 direct

    KARSEN PERRY A - Director

    2022-06-28 21:07:14 -0400 2022-06-24 A 20,000 a 20,000 direct

    DUNCAN BARBARA GAYLE - Director

    2022-06-28 21:02:17 -0400 2022-06-24 A 20,000 a 20,000 direct

    HIGGONS JOHN DUNCAN - Director

    2022-06-28 21:03:20 -0400 2022-06-24 A 20,000 a 20,000 direct

    DIAZ LUIS - Director

    2022-06-28 21:00:34 -0400 2022-06-24 A 20,000 a 20,000 direct

    IANNONE ROBERT - Director

    2022-06-28 21:05:21 -0400 2022-06-24 A 20,000 a 20,000 direct

    KAMEN ROBERT - Director

    2022-06-28 21:06:15 -0400 2022-06-24 A 20,000 a 20,000 direct

    RAYTHATHA JIGAR - Director

    2022-06-28 21:08:09 -0400 2022-06-24 A 20,000 a 20,000 direct

    SALTER-CID LUISA - Director

    2022-06-28 21:08:53 -0400 2022-06-24 A 20,000 a 20,000 direct

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    JOUNCE THERAPEUTICS INC JNCE 2022-08-16 22:15:05 UTC 1.081 1.239 1100000
    JOUNCE THERAPEUTICS INC JNCE 2022-08-16 21:45:03 UTC 1.081 1.239 1100000
    JOUNCE THERAPEUTICS INC JNCE 2022-08-16 21:15:03 UTC 1.081 1.239 1100000
    JOUNCE THERAPEUTICS INC JNCE 2022-08-16 20:45:05 UTC 1.081 1.239 1100000
    JOUNCE THERAPEUTICS INC JNCE 2022-08-16 20:15:04 UTC 1.081 1.239 1100000
    JOUNCE THERAPEUTICS INC JNCE 2022-08-16 19:45:04 UTC 1.081 1.239 1100000
    JOUNCE THERAPEUTICS INC JNCE 2022-08-16 19:15:05 UTC 1.081 1.239 1100000
    JOUNCE THERAPEUTICS INC JNCE 2022-08-16 18:45:04 UTC 1.081 1.239 1100000
    JOUNCE THERAPEUTICS INC JNCE 2022-08-16 18:15:05 UTC 1.081 1.239 1100000
    JOUNCE THERAPEUTICS INC JNCE 2022-08-16 17:45:04 UTC 1.081 1.239 1100000
    JOUNCE THERAPEUTICS INC JNCE 2022-08-16 17:15:04 UTC 1.081 1.239 1100000
    JOUNCE THERAPEUTICS INC JNCE 2022-08-16 16:45:04 UTC 1.081 1.239 1100000
    JOUNCE THERAPEUTICS INC JNCE 2022-08-16 16:15:04 UTC 1.081 1.239 1100000
    JOUNCE THERAPEUTICS INC JNCE 2022-08-16 15:45:04 UTC 1.081 1.239 1100000
    JOUNCE THERAPEUTICS INC JNCE 2022-08-16 15:15:03 UTC 1.081 1.239 1000000
    JOUNCE THERAPEUTICS INC JNCE 2022-08-16 14:45:03 UTC 1.081 1.239 1000000
    JOUNCE THERAPEUTICS INC JNCE 2022-08-16 14:15:04 UTC 1.081 1.239 1000000
    JOUNCE THERAPEUTICS INC JNCE 2022-08-16 13:45:05 UTC 1.081 1.239 1000000
    JOUNCE THERAPEUTICS INC JNCE 2022-08-16 13:15:04 UTC 1.081 1.239 1000000
    JOUNCE THERAPEUTICS INC JNCE 2022-08-16 12:45:03 UTC 1.081 1.239 1000000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin

    Elevate your investments